专用人群癌症登记数据在外对照试验中的可用性与相关性
该概念验证研究利用专用消化系统癌症登记数据,为两项III期随机对照试验构建外部对照臂,采用倾向性评分加权或匹配平衡组间基线特征,以Kaplan-Meier法和log-rank检验比较总生存。结果显示登记数据被认为适合使用,模拟对照臂与原始对照臂生存无显著差异。
要点
- 专用癌症登记数据可生成与原始对照臂相似的外部对照臂
- 混合对照臂中外部患者比例需适当约束
- 该策略有望降低临床试验成本与缩短 duration
核心结论
- 在适当选择患者的前提下,专用癌症登记数据可生成模拟对照臂的外部对照臂。
研究设计与样本
- 概念验证研究,利用专用消化系统癌症登记数据模拟PETACC-8和PRODIGE-13两项III期随机对照试验。
- PETACC-8模拟采用含约束比例外部患者的混合对照臂;PRODIGE-13模拟采用全外部对照臂和含50%外部患者的混合对照臂。
主要发现
- 两项试验中登记数据均被认为适合使用,模拟试验臂间患者基线特征平衡。
- 模拟PETACC-8中,混合对照臂的总生存与对照臂和实验臂均无差异。
- 模拟PRODIGE-13中,全外部对照臂模拟了对照臂,含50%外部数据的混合臂模拟了对照臂和实验臂。
关键数值与推荐
- 倾向性评分用于逆概率治疗加权或患者匹配。
- 绝对标准化均数差用于检验组间平衡。
- 总生存采用Kaplan-Meier估计,log-rank检验比较。
临床怎么用
- 在罕见癌症或按分子特征碎片化的常见癌症中,可考虑结合实验臂与专用癌症登记数据构建外部对照臂。
- 需适当选择患者以确保外部对照臂与原始对照臂可比。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Randomized clinical trials are becoming very challenging to perform in oncology, both in rare cancers and in more common cancers, fragmented according to molecular characteristics. In this proof of concept, we tested the feasibility of using data from a specialized digestive cancer registry as an external control arm in 2 phase III randomized clinical trials. METHODS: To emulate PETACC-8, the generated hybrid control arm comprised a constrained proportion of external patients. PRODIGE-13 was emulated through a fully external control arm and through a hybrid control arm containing 50% of external patients. Propensity scores were used either for inverse probability of treatment weighting or for patient matching. Absolute standardized mean differences were used to test the balance between arms. Overall survival was estimated using the Kaplan-Meier estimator and compared using the log-rank test. RESULTS: For both trials, registry data were considered fit-for-use despite different settings, and patient baseline characteristics were balanced between the emulated trial arms. In the emulated PETACC-8 trial, the overall survival of the hybrid control arms were not different from that of the control and experimental arms. In the emulation of PRODIGE-13, survival analyses showed that the fully external control arm mimicked the control arm and that the hybrid arm with 50% external data mimicked both control and experimental arms. Pending appropriate patient selection, the data from the Registry allowed the generation of external control arms mimicking control arms. CONCLUSION: This pilot study provides promising insights for improving the costs and duration of clinical trials by combining experimental arms with specialized cancer registry data.
引用
- Jooste V, Bouvier AM, Lepage C, et al. Usability and relevance of specialized population-based cancer registry data in externally controlled trials. J Clin Epidemiol. 2026. PMID: 42556756. doi:10.1016/j.jclinepi.2026.112442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。